The chaperone Clusterin in neurodegeneration−friend or foe?
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Fibrillar protein aggregates are the pathological hallmark of a group of age‐dependent neurodegenerative conditions, including Alzheimer's and Parkinson's disease. Aggregates of the microtubule‐associated protein Tau are observed in Alzheimer's disease and primary tauopathies. Tau pathology propagates from cell to cell in a prion‐like process that is likely subject to modulation by extracellular chaperones such as Clusterin. We recently reported that Clusterin delayed Tau fibril formation but enhanced the activity of Tau oligomers to seed aggregation of endogenous Tau in a cellular model. In contrast, Clusterin inhibited the propagation of α‐Synuclein aggregates associated with Parkinson's disease. These findings raise the possibility of a mechanistic link between Clusterin upregulation observed in Alzheimer's disease and the progression of Tau pathology. Here we review the diverse functions of Clusterin in the pathogenesis of neurodegenerative diseases, focusing on evidence that Clusterin may act either as a suppressor or enhancer of pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179 · cited 2×
“[132] Clusterin is mainly expressed in the brain by astrocytes[133] (Figure 3) and its expression is positively regulated by several cytokines, including the anti-inflammatory TGF-β[134] and the pro-inflammatory IL-1β,[135] which are secreted by activated microglia.[132] Thus, inflammation is likely one of the trigger…”
BackgroundHighly accurate protein structure prediction for the human proteome
Tunyasuvunakool, K., Adler, J., Wu, Z., Green, T., Zielinski, M., Žídek, A., Bridgland, A., Cowie, A., Meyer, C., Laydon, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03828-1 · Cited by 3,025 · cited 2×
“[14] (B) Predicted 3D-structure of Clusterin[27,28] (https://alphafold.”
BackgroundProtein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
Chiti, F., & Dobson, C. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045115 · Cited by 2,629 · cited 4×
“gates contribute to pathology by sequestering key cellular proteins and physically displacing organelle structures.[2,88] Chaperones, includ-”
BackgroundInfluentialZhang, Y., Sloan, S. A., Clarke, L. E., Caneda, C., Plaza, C. A., Blumenthal, P. D., Vogel, H., Steinberg, G. K., Edwards, M. S. B., Li, G., et al. (2016) · Neuron · doi:10.1016/j.neuron.2015.11.013 · Cited by 2,295 · cited 1×
“[132] Clusterin is mainly expressed in the brain by astrocytes[133] (Figure 3) and its expression is positively regulated by several cytokines, including the anti-inflammatory TGF-β[134] and the pro-inflammatory IL-1β,[135] which are secreted by activated microglia.”
Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., Sealock, J., Karlsson, I. K., Hägg, S., Athanasiu, L., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0311-9 · Cited by 2,277
Tau in physiology and pathology
Wang, Y., & Mandelkow, E. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.1 · Cited by 2,251 · cited 1×
“They differ in the number of N-terminal 29 amino acid inserts (0N, 1N, or 2N) and of microtubulebinding repeat domains (3Ror 4R).[94] Accumulation of hyperphosphorylated Tau in neurons facilitates the formation of fibrillar aggregates associated with AD and tauopathies (so-called neurofibrillary tangles and neuropil t…”
BackgroundStages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 8×
“Interestingly, Clusterin in turn seems to directly activate microglia, which would result in a positive feedback loop contributing to maintaining the chronic state of microglial activation observed in AD.”
BackgroundInfluentialThe Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990
Clearance systems in the brain—implications for Alzheimer disease
Tarasoff-Conway, J. M., Carare, R. O., Osorio, R. S., Glodzik, L., Butler, T., Fieremans, E., Axel, L., Rusinek, H., Nicholson, C., Zlokovic, B. V., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.119 · Cited by 1,678
Self-propagation of pathogenic protein aggregates in neurodegenerative diseases
Jucker, M., & Walker, L. C. (2013) · Nature · doi:10.1038/nature12481 · Cited by 1,663 · cited 1×
“[3,4] In this process, preexistent aggregate seeds catalyze the aggregation of normal versions of the same protein through a templating mechanism[5] (Figure 1), resulting in a disease-specific pattern of aggregate propagation through interconnected regions of the brain.[6] However, unlike the humanprion disease, there…”
BackgroundThe proteostasis network and its decline in ageing
Hipp, M. S., Kasturi, P., & Hartl, F. U. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0101-y · Cited by 1,642 · cited 1×
“gates contribute to pathology by sequestering key cellular proteins and physically displacing organelle structures.[2,88] Chaperones, includ-”
BackgroundSelf-citationDepletion of microglia and inhibition of exosome synthesis halt tau propagation
Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591
Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases
Soto, C., & Pritzkow, S. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0235-9 · Cited by 1,180 · cited 9×
“Interestingly, Clusterin in turn seems to directly activate microglia, which would result in a positive feedback loop contributing to maintaining the chronic state of microglial activation observed in AD.”
BackgroundInfluentialYeh, F. L., Wang, Y., Tom, I., Gonzalez, L. C., & Sheng, M. (2016) · Neuron · doi:10.1016/j.neuron.2016.06.015 · Cited by 943 · cited 6×
“[69,128] TREM2 variants linked to LOAD present with impaired binding and uptake of Clusterin-Aβ complexes, suggesting a protective role of TREM2 in Aβ clearance via Clusterin.[47] Recent research has identified LRP1 as an endocytic receptor for Tau uptake.”
BackgroundInfluentialStructure-based classification of tauopathies
Shi, Y., Zhang, W., Yang, Y., Murzin, A. G., Falcon, B., Kotecha, A., van Beers, M., Tarutani, A., Kametani, F., Garringer, H. J., et al. (2021) · Nature · doi:10.1038/s41586-021-03911-7 · Cited by 878 · cited 1×
“Specific tauopathies are linked with different fibril conformations in which the repeat domains and the 10 to 13 amino acids following them adopt distinct amyloid folds.[95] In healthy”
BackgroundHeparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds
Holmes, B. B., DeVos, S. L., Kfoury, N., Li, M., Jacks, R., Yanamandra, K., Ouidja, M. O., Brodsky, F. M., Marasa, J., Bagchi, D. P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301440110 · Cited by 859
Bell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., & Zlokovic, B. V. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600419 · Cited by 670
Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship
Nelson, P. T., Braak, H., & Markesbery, W. R. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181919a48 · Cited by 643 · cited 2×
“Free seed material in the extracellular space is substrate of extracellular chaperones such as Clusterin, with different outcomes: Clusterin may neutralize seeds of α -Synuclein ( α -Syn), but stabilize seeds of Tau.”
BackgroundPropagation of Tau aggregates and neurodegeneration
Goedert, M., Eisenberg, D. S., & Crowther, R. A. (2017) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-072116-031153 · Cited by 632 · cited 1×
“evidence to suggest that the aggregates found in other NDs are infectious and transmissible between individuals or species, hence the use of the term ‘‘prion-like’’.[7]”
BackgroundProtein transmission in neurodegenerative disease
Peng, C., Trojanowski, J. Q., & Lee, V. M.-Y. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0333-7 · Cited by 625
Maphis, N., Xu, G., Kokiko-Cochran, O. N., Jiang, S., Cardona, A., Ransohoff, R. M., Lamb, B. T., & Bhaskar, K. (2015) · Brain · doi:10.1093/brain/awv081 · Cited by 595
LRP1 is a master regulator of tau uptake and spread
Rauch, J. N., Luna, G., Guzman, E., Audouard, M., Challis, C., Sibih, Y. E., Leshuk, C., Hernandez, I., Wegmann, S., Hyman, B. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2156-5 · Cited by 541
Mechanisms of Aβ Clearance and Degradation by Glial Cells
Ries, M., & Sastre, M. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00160 · Cited by 527
Microglial exosomes facilitate α-synuclein transmission in Parkinson’s disease
Guo, M., Wang, J., Zhao, Y., Feng, Y., Han, S., Dong, Q., Cui, M., & Tieu, K. (2020) · Brain · doi:10.1093/brain/awaa090 · Cited by 522
Microglial activation and tau propagate jointly across Braak stages
Pascoal, T. A., Benedet, A. L., Ashton, N. J., Kang, M. S., Therriault, J., Chamoun, M., Savard, M., Lussier, F. Z., Tissot, C., Karikari, T. K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01456-w · Cited by 490
Reactive Glia not only Associates with Plaques but also Parallels Tangles in Alzheimer’s Disease
Serrano-Pozo, A., Mielke, M. L., Gómez-Isla, T., Betensky, R. A., Growdon, J. H., Frosch, M. P., & Hyman, B. T. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.05.047 · Cited by 488 · cited 1×
“Reactive microglia and astrocytes are located near Aβ plaques and Tau inclusions[102] and are thought to mediate aggregate clearance”
BackgroundPropagation and spread of pathogenic protein assemblies in neurodegenerative diseases
Jucker, M., & Walker, L. C. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0238-6 · Cited by 450 · cited 1×
“, α-Synuclein and Tau) may then propagate from cell to cell in a prion-like process that underlies disease progression.[3,4] In this process, preexistent aggregate seeds catalyze the aggregation of normal versions of the same protein through a templating mechanism[5] (Figure 1), resulting in a disease-specific pattern…”
BackgroundTotal and phosphorylated tau protein as biological markers of Alzheimer’s disease
Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., & Trojanowski, J. Q. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2009.10.010 · Cited by 389 · cited 1×
“[97,98] Indeed, seeding-competent Tau species have been detected in the CSF of AD patients[10,11] and Clusterin binding to Tau in patient brain has been reported.”
BackgroundClusterin in Alzheimer’s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies
Foster, E. M., Dangla-Valls, A., Lovestone, S., Ribe, E. M., & Buckley, N. J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00164 · Cited by 381
Takeda, S., Wegmann, S., Cho, H., DeVos, S. L., Commins, C., Roe, A. D., Nicholls, S. B., Carlson, G. A., Pitstick, R., Nobuhara, C. K., et al. (2015) · Nature Communications · doi:10.1038/ncomms9490 · Cited by 371
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
Hampel, H., Caraci, F., Cuello, A. C., Caruso, G., Nisticò, R., Corbo, M., Baldacci, F., Toschi, N., Garaci, F., Chiesa, P. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00456 · Cited by 360 · cited 1×
“response, providing support for the critical role of neuroinflammation in AD pathogenesis.[131] An upregulation of inflammation-related”
BackgroundDeMattos, R. B., O'dell, M. A., Parsadanian, M., Taylor, J. W., Harmony, J. A. K., Bales, K. R., Paul, S. M., Aronow, B. J., & Holtzman, D. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162228299 · Cited by 359
Oda, T., Wals, P., Osterburg, H. H., Johnson, S. A., Pasinetti, G. M., Morgan, T. E., Rozovsky, I., Stine, W. B., Snyder, S. W., Holzman, T. F., et al. (1995) · Experimental Neurology · doi:10.1006/exnr.1995.1080 · Cited by 352
Expression of Novel Alzheimer’s Disease Risk Genes in Control and Alzheimer’s Disease Brains
Karch, C. M., Jeng, A. T., Nowotny, P., Cady, J., Cruchaga, C., & Goate, A. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050976 · Cited by 328 · cited 1×
“LOAD risk variants of CLU have been associated with either unchanged,[16,17] increased[73,75] or decreased[22,77] Clusterin levels in the brain, plasma or CSF of AD patients when compared to AD patients with a normal CLU gene.”
ResultMechanisms of secretion and spreading of pathological tau protein
Brunello, C. A., Merezhko, M., Uronen, R.-L., & Huttunen, H. J. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03349-1 · Cited by 304 · cited 2×
“reach the extracellular environment via release from dying cells or upon active secretion by neurons, which may occur through a transsynaptic mechanism[8] or in a manner facilitated by chaperones, such as the HSP40 protein DnaJC5.”
BackgroundSöllvander, S., Nikitidou, E., Brolin, R., Söderberg, L., Sehlin, D., Lannfelt, L., & Erlandsson, A. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0098-z · Cited by 267
Rostami, J., Mothes, T., Kolahdouzan, M., Eriksson, O., Moslem, M., Bergström, J., Ingelsson, M., O’Callaghan, P., Healy, L. M., Falk, A., et al. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02158-3 · Cited by 239
Plasma clusterin and the risk of Alzheimer disease
Schrijvers, E. M. C. (2011) · JAMA · doi:10.1001/jama.2011.381 · Cited by 220
Hsieh, Y.-C., Guo, C., Yalamanchili, H. K., Abreha, M., Al-Ouran, R., Li, Y., Dammer, E. B., Lah, J. J., Levey, A. I., Bennett, D. A., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.104 · Cited by 196 · cited 2×
“[103,114] Clusterin binds to extracellular aggregates and promotes their clearance via receptor mediated endocytosis.[14,99,119,120] Accord-”
BackgroundMethodChen, J. J., Nathaniel, D. L., Raghavan, P., Nelson, M., Tian, R., Tse, E., Hong, J. Y., See, S. K., Mok, S.-A., Hein, M. Y., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009432 · Cited by 170 · cited 1×
“Notably, a fraction of internalized aggregates may escape from the endolyso-somal pathway to the cytoplasm where they can act as seeds in templating aggregation of endogenous native protein [14,110,111] (Figure 1 and 3).”
BackgroundSP-40,40 is a constituent of Alzheimer's amyloid
Choi-Miura, N. H., Ihara, Y., Fukuchi, K., Takeda, M., Nakano, Y., Tobe, T., & Tomita, M. (1992) · Acta Neuropathologica · doi:10.1007/bf00296787 · Cited by 158
Brelstaff, J. H., Mason, M., Katsinelos, T., McEwan, W. A., Ghetti, B., Tolkovsky, A. M., & Spillantini, M. G. (2021) · Science Advances · doi:10.1126/sciadv.abg4980 · Cited by 135
Reactive microglia enhance the transmission of exosomal α-synuclein via toll-like receptor 2
Xia, Y., Zhang, G., Kou, L., Yin, S., Han, C., Hu, J., Wan, F., Sun, Y., Wu, J., Li, Y., et al. (2021) · Brain · doi:10.1093/brain/awab122 · Cited by 123
Cooper, J. M., Lathuiliere, A., Migliorini, M., Arai, A. L., Wani, M. M., Dujardin, S., Muratoglu, S. C., Hyman, B. T., & Strickland, D. K. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100715 · Cited by 122 · cited 2×
“dation, it promoted seeding of endogenous Tau aggregation by uptake of pathological Tau forms.[129] Stabilization of Tau seeds by Clusterin”
BackgroundTakeda, S., Commins, C., DeVos, S. L., Nobuhara, C. K., Wegmann, S., Roe, A. D., Costantino, I., Fan, Z., Nicholls, S. B., Sherman, A. E., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24716 · Cited by 113
Leeb, C., Eresheim, C., & Nimpf, J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.529271 · Cited by 99 · cited 1×
“…receptors, [119] heparan sulfate proteoglycans (HSPGs), [120] apolipoprotein E receptor 2 (ApoER2), very low density lipoprotein receptor (VLDLR), [122] triggering receptor expressed on myeloid cells 2 (TREM2), [47] Plexin A4, [123] and low density lipoprotein receptor-related proteins 1 and 2…”
BackgroundMicroglia display modest phagocytic capacity for extracellular tau oligomers
Majerova, P., Zilkova, M., Kazmerova, Z., Kovac, A., Paholikova, K., Kovacech, B., Zilka, N., & Novak, M. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0161-z · Cited by 90 · cited 1×
“[136] Interestingly, activated microglia appear to be more efficient in Tau internalization and promoting spreading than quiescent microglia,[105,113] and microglial activation correlates with propagation of Tau pathology.”
BackgroundGiannakopoulos, P., Kövari, E., French, L. E., Viard, I., Hof, P. R., & Bouras, C. (1998) · Acta Neuropathologica · doi:10.1007/s004010050815 · Cited by 90 · cited 1×
“[13] While its colocalization with Aβ deposits in the extracellular spacehasbeen studiedextensively,[66,67] thephysiological consequences of these interactions are not well understood.”
BackgroundPLXNA4 is associated with Alzheimer disease and modulates tau phosphorylation
Jun, G., Asai, H., Zeldich, E., Drapeau, E., Chen, C., Chung, J., Park, J., Kim, S., Haroutunian, V., Foroud, T., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24219 · Cited by 67
A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin
Deming, Y., Xia, J., Cai, Y., Lord, J., Holmans, P., Bertelsen, S., Holtzman, D., Morris, J. C., Bales, K., Pickering, E. H., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.09.009 · Cited by 66 · cited 1×
“LOAD risk variants of CLU have been associated with either unchanged,[16,17] increased[73,75] or decreased[22,77] Clusterin levels in the brain, plasma or CSF of AD patients when compared to AD patients with a normal CLU gene.”
ResultApolipoprotein J (clusterin) activates rodent microglia in vivo and in vitro
Xie, Z., Harris‐White, M. E., Wals, P. A., Frautschy, S. A., Finch, C. E., & Morgan, T. E. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03065.x · Cited by 53 · cited 8×
“Interestingly, Clusterin in turn seems to directly activate microglia, which would result in a positive feedback loop contributing to maintaining the chronic state of microglial activation observed in AD.”
BackgroundInfluential
Research works printed but not linked: 87
- 10.1038/s41576‐018‐0011‐4 · DOI · Paper page
- 10.1002/mds.27646 · DOI · Paper page
- 10.1186/s40478‐019‐0777‐4 · DOI · Paper page
- 10.1146/annurev‐biochem‐072711‐163904 · DOI · Paper page
- 10.1038/s41467‐021‐25060‐1 · DOI · Paper page
- 10.1186/s13195‐017‐0319‐x · DOI
- 10.1515/bmc‐2015‐0026 · DOI · Paper page
- 10.3233/JAD‐2011‐111844 · DOI · Paper page
- 10.1177/0004563213503456 · DOI
- 10.1016/S0021-9258(18)32238-5 · DOI · Paper page
- 10.1083/jcb.105.6.2735 · DOI · Paper page
- 10.1159/000366365 · DOI · Paper page
- 10.1093/nar/gkaa913 · DOI · Paper page
- 10.1002/pro.5560061007 · DOI · Paper page
- 10.1038/sj.emboj.7600016 · DOI · Paper page
- 10.1096/fj.06‐7986com · DOI · Paper page
- 10.1021/bi5011249 · DOI
- 10.1186/s40478‐017‐0481‐1 · DOI · Paper page
- 10.1186/s40478‐020‐01079‐1 · DOI
- 10.1038/s41594‐018‐0057‐1 · DOI · Paper page
- 10.1016/j.celrep.2018.05.074 · DOI · Paper page
- 10.1021/bi010135x · DOI · Paper page
- 10.1111/j.1432‐1033.1994.tb18807.x · DOI · Paper page
- 10.1016/j.bone.2018.02.018 · DOI
- 10.1016/j.bbcan.2020.188500 · DOI
- 10.1172/JCI113531 · DOI · Paper page
- 10.1038/s41467‐021‐26366‐w · DOI · Paper page
- 10.1016/S0021-9258(19)38290-0 · DOI · Paper page
- Suzuki T., 2002, Predominant apolipoprotein J exists as lipid‐poor mixtures in cerebrospinal fluid, Annals of Clinical and Laboratory Science, 32, 369
- 10.1186/s13195‐019‐0498‐8 · DOI · Paper page
- 10.1111/j.1600‐0854.2007.00549.x · DOI · Paper page
- 10.1074/jbc.M111.252957 · DOI
- 10.1016/j.tibs.2021.01.005 · DOI
- 10.3389/fnins.2018.00504 · DOI · Paper page
- 10.1042/BJ20051190 · DOI · Paper page
- 10.2174/1389203718666170918155247 · DOI
- 10.1126/sciadv.aau3112 · DOI · Paper page
- 10.1038/nsmb.2191 · DOI · Paper page
- 10.1074/jbc.M115.689539 · DOI · Paper page
- 10.1186/s13024‐020‐00416‐1 · DOI · Paper page
- 10.1186/s12868‐018‐0402‐7 · DOI
- 10.1186/s13024‐021‐00426‐7 · DOI · Paper page
- 10.1073/pnas.1701137114 · DOI · Paper page
- 10.1111/bpa.12660 · DOI · Paper page
- 10.1021/ja3103567 · DOI · Paper page
- 10.1073/pnas.95.11.6448 · DOI · Paper page
- 10.1093/brain/awaa223 · DOI · Paper page
- 10.1038/ng.439 · DOI · Paper page
- 10.1186/s13024‐015‐0024‐9 · DOI · Paper page
- 10.1038/tp.2011.17 · DOI · Paper page
- 10.1371/journal.pone.0095152 · DOI · Paper page
- 10.1016/j.exer.2014.07.005 · DOI
- 10.1093/hmg/ddx329 · DOI
- 10.1212/WNL.0b013e3182605801 · DOI · Paper page
- 10.1038/srep26027 · DOI · Paper page
- 10.1016/j.neuropsychologia.2013.12.020 · DOI · Paper page
- 10.1016/j.jpsychires.2020.07.015 · DOI
- 10.1016/j.jalz.2014.10.012 · DOI · Paper page
- 10.2174/1567205013666160703180531 · DOI
- 10.1038/s41591‐018‐0206‐4 · DOI · Paper page
- 10.1016/j.neurobiolaging.2019.10.025 · DOI · Paper page
- 10.1371/journal.pone.0190478 · DOI
- 10.1210/en.2013‐1870 · DOI
- 10.1039/c4cp05563b · DOI · Paper page
- 10.1038/ncomms10948 · DOI · Paper page
- 10.1007/s12551‐017‐0289‐z · DOI
- 10.1093/emboj/16.7.1501 · DOI · Paper page
- 10.1038/ncomms13673 · DOI · Paper page
- 10.1016/j.tibs.2021.12.009 · DOI
- 10.15252/embj.201593489 · DOI · Paper page
- Wu S. Sirkis D. W. &Schekman R.(2022). Unconventional secretion of α‐synuclein mediated by palmitoylated DNAJC5 oligomers.bioRxiv. 2022.027.477991.https://doi.org/10.1101/2022.01.27.477991 · doi:10.1101/2022.01.27.477991
- 10.1371/journal.pone.0103187 · DOI · Paper page
- 10.1016/j.bbih.2021.100242 · DOI · Paper page
- 10.3389/fncel.2019.00403 · DOI · Paper page
- 10.1007/s00401‐017‐1722‐x · DOI · Paper page
- 10.1007/s00018‐011‐0684‐8 · DOI · Paper page
- 10.1083/jcb.201911126 · DOI
- 10.1007/s00702‐010‐0462‐z · DOI
- 10.1093/hmg/ddw188 · DOI
- 10.1038/ncomms2896 · DOI
- 10.1006/excr.2001.5358 · DOI
- 10.1242/jcs.228213 · DOI · Paper page
- 10.1016/0165‐5728(94)00194‐s · DOI
- 10.1006/mcne.1994.1027 · DOI
- 10.1146/annurev‐neuro‐061010‐113810 · DOI · Paper page
- 10.1186/s12974‐020‐02024‐8 · DOI · Paper page
- 10.1093/bioinformatics/15.4.305 · DOI · Paper page
Cited by
The role of genetic risk factors of Alzheimer’s disease in synaptic dysfunction
Fu, W.-Y., & Ip, N. Y. (2023) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2022.07.011 · Cited by 48
The selenoprotein methionine sulfoxide reductase B1 (MSRB1)
Tarrago, L., Kaya, A., Kim, H.-Y., Manta, B., Lee, B.-C., & Gladyshev, V. N. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.08.043 · Cited by 39
The Role of Genetic, Environmental, and Dietary Factors in Alzheimer’s Disease: A Narrative Review
Mertaş, B., & Boşgelmez, İ. İ. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031222 · Cited by 35
Genetic associations with age at dementia onset in the PSEN1 E280A Colombian kindred
Cochran, J. N., Acosta‐Uribe, J., Esposito, B. T., Madrigal, L., Aguillón, D., Giraldo, M. M., Taylor, J. W., Bradley, J., Fulton‐Howard, B., Andrews, S. J., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13021 · Cited by 21
Metadata
- Authors
- Yuste‐Checa, P., Bracher, A., & Hartl, F. U.
- Venue
- BioEssays
- Publisher
- Wiley
- Published
- 2022-05-06
- Volume
- 44
- Issue
- 7
- Pages
- e2100287-e2100287
- ISSN
- 0265-9247 (ISSN-L)
- 1521-1878
- OpenAlex
- W4229006902
- Cited by
- 37
- References
- 53
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.